Febuxostat for Hyperuricemia in Patients with Advanced Chronic Kidney Disease

被引：25

作者：

Akimoto, Tetsu ^{[1
,2
]}

Morishita, Yoshiyuki ^{[1
,3
,4
]}

Ito, Chiharu ^{[1
,3
,4
]}

Iimura, Osamu ^{[3
]}

Tsunematsu, Sadao ^{[4
]}

Watanabe, Yuko ^{[1
]}

Kusano, Eiji ^{[1
]}

Nagata, Daisuke ^{[1
]}

机构：

[1] Jichi Med Univ, Dept Internal Med, Div Nephrol, Shimotsuke, Tochigi, Japan

[2] Green Town Clin, Shimotsuke, Tochigi, Japan

[3] Kumakura Clin, Utsunomiya, Tochigi, Japan

[4] Yuki Clin, Ibaraki, Japan

来源：

DRUG TARGET INSIGHTS | 2014年 / 8卷

关键词：

febuxostat; chronic kidney disease; hemodialysis; uric acid; oxidative stress;

D O I：

10.4137/DTI.S16524

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Febuxostat is a nonpurine xanthine oxidase (XO) inhibitor, which recently received marketing approval. However, information regarding the experience with this agent among advanced chronic kidney disease (CKD) patients is limited. In the current study, we investigated the effects of oral febuxostat in patients with advanced CKD with asymptomatic hyperuricemia. We demonstrated, for the first time, that not only the serum levels of uric acid (UA) but also those of 8-hydroxydeoxyguanosine, an oxidative stress marker, were significantly reduced after six months of febuxostat treatment, with no adverse events. These results encouraged us to pursue further investigations regarding the clinical impact of lowering the serum UA levels with febuxostat in advanced CKD patients in terms of concomitantly reducing oxidative stress via the blockade of XO. More detailed studies with a larger number of subjects and assessments of the effects of multiple factors affecting hyperuricemia, such as age, sex, and dietary habits, would shed light on the therapeutic challenges of treating asymptomatic hyperuricemia in patients with various stages of CKD.

引用

页码：39 / 43

页数：5

共 28 条

[1] Effect of Allopurinol on Blood Pressure: A Systematic Review and Meta-Analysis [J].

Agarwal, Vikram ;

Hans, Nidhi ;

Messerli, Franz H. .

JOURNAL OF CLINICAL HYPERTENSION, 2013, 15 (06) :435-442

[2] Seasonal changes in blood pressure in patients with end-stage renal disease treated with hemodialysis [J].

Argilés, A ;

Mourad, G ;

Mion, C .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (19) :1364-1370

[3] Febuxostat compared with allopurinol in patients with hyperuricemia and gout [J].

Becker, MA ;

Schumacher, HR ;

Wortmann, RL ;

MacDonald, PA ;

Eustace, D ;

Palo, WA ;

Streit, J ;

Joseph-Ridge, N .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (23) :2450-2461

[4]

Dalbeth N, 2006, J RHEUMATOL, V33, P1646

[5] Managing gout: How is it different in patients with chronic kidney disease? [J].

El-Zawawy, Hossam ;

Mandell, Brian F. .

CLEVELAND CLINIC JOURNAL OF MEDICINE, 2010, 77 (12) :919-928

[6] EFFICACY OF BENZBROMARONE IN HYPERURICEMIC PATIENTS ASSOCIATED WITH CHRONIC KIDNEY DISEASE [J].

Fujimori, S. ;

Ooyama, K. ;

Ooyama, H. ;

Moromizato, H. .

NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2011, 30 (12) :1035-1038

[7]

Gaffo AL, 2009, CORE EVID, V4, P25

[8] High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid [J].

George, Jacob ;

Carr, Elaine ;

Davies, Justine ;

Belch, J. J. F. ;

Struthers, Allan .

CIRCULATION, 2006, 114 (23) :2508-2516

[9]

George Jacob, 2009, Ther Clin Risk Manag, V5, P799

[10] Redox regulation of protein damage in plasma [J].

Griffiths, Helen R. ;

Dias, Irundika H. K. ;

Willetts, Rachel S. ;

Devitt, Andrew .

REDOX BIOLOGY, 2014, 2 :430-435

← 1 2 3 →